Darolutamide Stands Out in the Pool of 2nd Generation Antiandrogen Therapies
Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.
Eleni Efstathiou, MD, PhD, an oncology specialist at the University of Texas MD Anderson Cancer Center provides background on the ARAMIS trial of darolutamide (Nubeqa) compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Back in 2006, agents like abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) were being developed, oncologists at the time believed that the field was becoming saturated with antiandrogentherapies. Efstathiou says, that what is interesting about darolutamide, is that it has the ability to cross the blood-brain barrier. This sets darolutamide apart from enzalutamide and apalutamide, especially, because the mechanism of action for these 2 agents are almost identical.
Overall, the profile of darolutamide makes it ideal to help improve quality of life in patients with nmCRPC, Efstathiou explains.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
